Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Selution SLR
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: MedAlliance
Deal Size: $1,135.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 18, 2022